Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib

Atopic dermatitis (AD) is a clinically heterogenous, inflammatory skin condition with a high impact on patients’ daily activities that remains difficult to treat. The knowledge acquired over the last decade on AD pathophysiology and disease burden led to the development of new targeted therapeutic o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogueira, Miguel, Torres, Tiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648435/
https://www.ncbi.nlm.nih.gov/pubmed/35024237
http://dx.doi.org/10.5826/dpc.1104a145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648435/
https://www.ncbi.nlm.nih.gov/pubmed/35024237
http://dx.doi.org/10.5826/dpc.1104a145

Ejemplares similares